EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Metabolic dysfunction-associated steatotic liver disease and type 2 diabetes: Pathophysiology, diagnosis, and emerging therapeutic strategies

Mithil Gowda Suresh, Safia Mohamed, Harinivaas S Geetha, Sushmita Prabhu, Nitin Trivedi, Zhu C Ng, Priyal D Mehta, Ajit S Brar, Aalam Sohal, Manjeet K Goyal, Juniali Hatwal, Akash Batta

World Journal of Diabetes · 15.02.2026 · 17 (2)

DOI: 10.4239/wjd.v17.i2.113149 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift World Journal of Diabetes, online erschienen am 15.02.2026. Verfasst von Mithil Gowda Suresh und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Saint Vincent Hospital, Worcester, MA 01608, United States. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 166 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic dysfunction-associated steatotic liver disease (MASLD), the updated terminology for fatty liver disease linked to metabolic dysfunction, is highly prevalent among individuals with type 2 diabetes mellitus (T2DM). MASLD affects a majority of patients with T2DM and markedly increases the risk of fibrosis, cirrhosis, hepatocellular carcinoma, and cardiovascular mortality. The pathogenesis in diabetic populations reflects a convergence of insulin resistance, dyslipidemia, mitochondrial dysfunction, chronic inflammation, and genetic predisposition. Advances in non-invasive diagnostics, including elastography and serum biomarkers, enable earlier identification and staging of disease, though limitations remain in diabetic cohorts. Lifestyle modification is the cornerstone of therapy, yet emerging pharmacotherapies are reshaping the therapeutic landscape. Antidiabetic agents such as glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter-2 inhibitors, and pioglitazone show hepatic benefits beyond glycemic control, while novel agents and combination regimens are under active evaluation. This narrative review synthesizes current evidence on epidemiology, mechanisms, diagnostics, and therapeutics of MASLD in T2DM, and highlights future directions in precision medicine. Integration of multidisciplinary care is essential to address this converging epidemic.

Schlagwörter

Stichwörter der Autor:innen

Fatty liverGlucagon-like peptide-1 receptor agonistsHepatic fibrosisInsulin resistanceMetabolic associated steatohepatitisMetabolic dysfunction-associated steatotic liver diseaseNon-invasive diagnosticsPersonalized medicineSodium-glucose cotransporter-2 inhibitorsType 2 diabetes mellitus

Autor:innen und Institutionen

  • Department of Internal Medicine, Saint Vincent Hospital, Worcester, MA 01608, United States.
  • Department of Medicine and Surgery, University of Massachusetts Chan Medical School-Baystate Medical Center, Springfield, MA 01199, United States.
  • Department of Internal Medicine, Michigan State University at Hurley Medical Center, Flint, MI 48503, United States.
  • Department of Gastroenterology and Hepatology, Creighton University School of Medicine, Phoenix, AZ 85012, United States.
  • Department of Internal Medicine, Cleveland Clinic Akron General Hospital, Akron, OH 110029, United States.
  • Department of Internal Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh 160012, India.

Zitieren

APA

Suresh, M. G., Mohamed, S., Geetha, H. S., Prabhu, S., Trivedi, N., Ng, Z. C., Mehta, P. D., Brar, A. S., Sohal, A., Goyal, M. K., Hatwal, J., & Batta, A. (2026). Metabolic dysfunction-associated steatotic liver disease and type 2 diabetes: Pathophysiology, diagnosis, and emerging therapeutic strategies. World Journal of Diabetes, 17(2). https://doi.org/10.4239/wjd.v17.i2.113149

Vancouver

Suresh MG, Mohamed S, Geetha HS, Prabhu S, Trivedi N, Ng ZC, et al. Metabolic dysfunction-associated steatotic liver disease and type 2 diabetes: Pathophysiology, diagnosis, and emerging therapeutic strategies. World Journal of Diabetes. 2026;17(2). doi:10.4239/wjd.v17.i2.113149

BibTeX
@article{Suresh2026,
  author = {Suresh, Mithil Gowda and Mohamed, Safia and Geetha, Harinivaas S and Prabhu, Sushmita and Trivedi, Nitin and Ng, Zhu C and Mehta, Priyal D and Brar, Ajit S and Sohal, Aalam and Goyal, Manjeet K and Hatwal, Juniali and Batta, Akash},
  title = {Metabolic dysfunction-associated steatotic liver disease and type 2 diabetes: Pathophysiology, diagnosis, and emerging therapeutic strategies},
  journal = {World Journal of Diabetes},
  year = {2026},
  volume = {17},
  number = {2},
  doi = {10.4239/wjd.v17.i2.113149}
}
Kostenlos starten →